GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Net Income From Continuing Operations

Affimed NV (Affimed NV) Net Income From Continuing Operations : $-114.12 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Affimed NV's net income from continuing operations for the three months ended in Dec. 2023 was $-22.03 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was $-114.12 Mil.


Affimed NV Net Income From Continuing Operations Historical Data

The historical data trend for Affimed NV's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Net Income From Continuing Operations Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.96 -50.32 -65.00 -91.11 -115.53

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.42 -34.24 -31.85 -25.99 -22.03

Affimed NV Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-114.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affimed NV (Affimed NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Net Income From Continuing Operations
Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (Affimed NV) Headlines

From GuruFocus

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

By Stock market mentor Stock market mentor 02-08-2023

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

By Stock market mentor Stock market mentor 01-09-2023

Affimed Announces Annual General Meeting of Shareholders

By sperokesalga sperokesalga 05-22-2023